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Background
ALVAC-HIV prime/HIV-1 Env protein boost regimens
have shown HIV-specific neutralizing antibody (NAb)
and cell-mediated immune responses, but the impact of
protein subunit schedule and adjuvant requires further
definition.
Methods
A Phase 1 trial was conducted in two parts. In Part A,
(open-label) 19 volunteers received oligomeric gp160
MN/LAI-2 (ogp160) with a dose escalation (25, 50, 100
μg). In Part B, 72 volunteers (60 active, 12 placebo)
received placebo or recombinant canarypox expressing
HIV-1 antigens, (ALVAC-HIV, vCP205) prime with dif-
ferent doses and schedules of ogp160MN/LAI-2 in alum
or polyphosphazene (PCPP).
Results
The vaccines were safe and well tolerated with no vac-
cine-related serious adverse events. Cumulative chro-
mium release CTL frequency was 37%, and 54% of
volunteers showed proliferative responses to HIV anti-
gens. Lymphoproliferative CD4+, HIV-specific responses
were seen in 53% of ogp160 only and 57% of prime-
boost recipients, respectively. Induced binding antibody
to ogp160 was dose-dependent. NAb responses to vac-
cine homologous Tier 1 HIV-1 MN were seen in 99% of
vaccine recipients. While NAb to the heterologous Tier
2 US-1 (R5, clade B) pseudovirus was negative in all
volunteers tested using TZM-bl cells, in a PBMC-based
assay, US-1 primary isolate Nab was induced in 2/19
(10.5%) recipients of ogp160 protein alone and in 5/30
(16.7%) prime-boost volunteers who received ogp160 in
PCPP. Primary isolate neutralization was observed more
frequently overall in recipients of ogp160 in PCPP, as
compared with alum (p=0.027). Using an intracellular
p24 flow-cytometry assay, sera from an ALVAC-HIV/
ogp160 recipient demonstrated 94% neutralization of
US-1.
Conclusion
A small percentage of vaccine recipients developed Nab
to heterologous primary isolates, responses that to our
knowledge have not been previously described. These
results constitute proof of concept that Tier 2 NAb can
be elicited by vaccination in humans, and underscore
the importance of further optimization of prime-boost
vaccination and adjuvanting strategies for HIV-1
prevention.
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